IPSEN (OTCMKTS:IPSEY) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened

IPSEN (OTCMKTS:IPSEY)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $32.76 and traded as high as $36.03. IPSEN shares last traded at $36.03, with a volume of 305 shares trading hands.

Analysts Set New Price Targets

Several analysts have issued reports on IPSEY shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research note on Monday, November 3rd. BNP Paribas cut shares of IPSEN to an “underperform” rating in a report on Wednesday, November 26th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

IPSEN Price Performance

The business’s 50 day moving average is $35.08 and its two-hundred day moving average is $32.76.

IPSEN Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.